Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5046-5053

  Berti, Andrew D ^a   Wergin, Justine E ^a   Girdaukas, Gary G ^a   Hetzel, Scott J ^b   Sakoulas, George ^c   Rose, Warren E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CELL WALL; CLARITHROMYCIN; DAPTOMYCIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXACILLIN;

EID: 84866332806     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00502-12     Document Type: Article

References (52)

1. Ahmad NM, Rojtman AD. 2010. Successful treatment of daptomycin- nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ann. Pharmacother. 44:918-921.
2. Arciola CR, Baldassarri L, Montanaro L. 2001. Presence of icaA and icaD genes and slime production in a collection of staphylococcal strains from catheter-associated infections. J. Clin. Microbiol. 39:2151-2156. (Pubitemid 32531474)
3. Bayer AS, et al. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect. Immun. 68:3548-3553. (Pubitemid 30340456)
4. Bonhoeffer S, Lipsitch M, Levin BR. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 94:12106-12111. (Pubitemid 27467850)
5. Chamberlain NR, et al. 1991. Correlation of carotenoid production, decreased membrane fluidity, and resistance to oleic acid killing in Staphylococcus aureus 18Z. Infect. Immun. 59:4332-4337.
6. Chen LY, et al. 2011. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect. Dis. 11:152.
7. Clinical and Laboratory Standards Institute. 2010. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - tenth edition. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Credito K, Lin G, Appelbaum PC. 2007. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 51:1504-1507. (Pubitemid 46586838)
9. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
10. Dhand A, et al. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
11. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. (Pubitemid 36368592)
12. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451-456.
13. Fischer A, et al. 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66:1696-1711.
14. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
15. Garrigos C, et al. 2010. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5251-5256.
16. Holm S. 1979. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6:65-70.
17. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047. (Pubitemid 44396410)
18. Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO. 2011. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn. Microbiol. Infect. Dis. 71:286-290.
19. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060.
20. Lefebvre M, et al. 2010. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int. J. Antimicrob. Agents 36:542-544.
21. Mangili A, Bica I, Snydman DR, Hamer DH. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060. (Pubitemid 40418318)
22. Martin PK, Li T, Sun D, Biek DP, Schmid MB. 1999. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J. Bacteriol. 181:3666-3673. (Pubitemid 29283792)
23. Matsuo M, et al. 2011. Mutation of RNA polymerase β subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob. Agents Chemother. 55:4188-4195.
24. Mishra NN, et al. 2011. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55:526-531.
25. Mishra NN, et al. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4012-4018.
26. Mishra NN, et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
27. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624.
28. Naimi TS, et al. 2003. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin. Infect. Dis. 36:1609-1612. (Pubitemid 36783347)
29. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54:4329-4334.
30. Patel D, et al. 2011. Mechanisms of in-vitro-selected daptomycin-nonsusceptibility in Staphylococcus aureus. Int. J. Antimicrob. Agents 38:442- 446.
31. Poeppl W, et al. 2011. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob. Agents Chemother. 55:4999-5003.
32. Rand KH, Houck HJ. 2004. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2871-2875. (Pubitemid 38989149)
33. Rice LB, Eliopoulos GM, Moellering RC, Jr. 1989. In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob. Agents Chemother. 33:470-473. (Pubitemid 19094275)
34. Rose WE, Knier RM, Hutson PR. 2010. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 65:2149-2154.
35. Rose WE, et al. 2008. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:831-836. (Pubitemid 351358359)
36. Sader HS, Moet GJ, Farrell DJ, Jones RN. 2011. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillinresistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn. Microbiol. Infect. Dis. 70:412-416.
37. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
38. Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC. 2011. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:4589-4593.
39. Sheridan KR, Potoski BA, Shields RK, Nau GJ. 2010. Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis. Pharmacotherapy 30:1247-1251.
40. Silverman JA, Oliver N, Andrew T, Li T. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802. (Pubitemid 32466351)
41. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544. (Pubitemid 36919456)
42. Steed ME, Vidaillac C, Rybak MJ. 2010. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob. Agents Chemother. 54:5187-5192.
43. Steenbergen JN, Alder J, Thorne GM, Tally FP. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288. (Pubitemid 40425449)
44. Steenbergen JN, Mohr JF, Thorne GM. 2009. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J. Antimicrob. Chemother. 64:1130-1138.
45. Traunmuller F, et al. 2010. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. 65:1252-1257.
46. Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. 1989. Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J. Bacteriol. 171:2882-2885. (Pubitemid 19125102)
47. Vignaroli C, Rinaldi C, Varaldo PE. 2011. Striking "seesaw effect" between daptomycin nonsusceptibility and beta-lactam susceptibility in Staphylococcus haemolyticus. Antimicrob. Agents Chemother. 55:2495-2497.
48. Walsh TR, et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444. (Pubitemid 32606216)
49. Yang SJ, et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
50. Yang SJ, et al. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54:3079-3085.
51. Yang SJ, et al. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54: 3161-3169.
52. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5026-5033. (Pubitemid 41483999)